We examined direct effects of GLP-1 analogues on abdominal AT depots, which are prone to expand with increasing obesity and susceptible to AT dysfunction.15 Our study shows that acute treatments based on GLP-1 analogues may have an advantage by increasing adiponectin expression and that they reduce elastin secretion by which they take part in ECM remodelling. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.